Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 141 | 7,082 | 30% |
| 2020 | 120 | 6,017 | 33% |
| 2021 | 142 | 6,685 | 37% |
| 2022 | 134 | 6,321 | 42% |
| 2023 | 143 | 6,407 | 45% |
| 2024 | 148 | 6,158 | 47% |
| 2025 from claims | – | 6,332 5,811–6,700 | 48% |
| 2026 forecast | – | 6,436 5,663–7,427 | 48% |
| 2027 forecast | – | 6,484 5,543–7,727 | 48% |
| 2028 forecast | – | 6,532 5,450–7,998 | 49% |
| 2029 forecast | – | 6,580 5,374–8,252 | 50% |
| 2030 forecast | – | 6,627 5,309–8,492 | 50% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 19% of the cases CMS names in Illinois; 95 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 12% inpatient hospital, 75% hospital outpatient, 13% surgery center. The share outside the hospital has moved −4 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 150 | 6,970−0.5%/yr | −0.5%/yr | 6.4 | 12% | 7,740 in 2030+1.8%/yr |
| Indiana | 105 | 5,228−0.5%/yr | −0.5%/yr | 7.5 | 11% | 6,130 in 2030+2.7%/yr |
| Michigan | 94 | 4,688−5.4%/yr | −5.4%/yr | 5.6 | 6% | 4,480 in 2030−0.8%/yr |
| Missouri | 83 | 3,766−2.6%/yr | −2.6%/yr | 6.1 | 19% | 4,330 in 2030+2.4%/yr |
| Wisconsin | 63 | 2,490−3.4%/yr | −3.4%/yr | 4.5 | 6% | 2,900 in 2030+2.6%/yr |
| Kansas | 44 | 2,107−0.8%/yr | −0.8%/yr | 5.2 | 20% | 2,660 in 2030+4%/yr |
| Minnesota | 47 | 1,837−5.2%/yr | −5.2%/yr | 4.1 | 5% | 2,500 in 2030+5.3%/yr |
| Iowa | 47 | 1,750−0.8%/yr | −0.8%/yr | 4.0 | 26% | 1,840 in 2030+0.9%/yr |
| Nebraska | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.8 | 12% | 1,880 in 2030+3.7%/yr |
| South Dakota | 18 | 618+1.8%/yr | +1.8%/yr | 4.8 | 0% | 810 in 2030+4.6%/yr |
| North Dakota | 10 | 352−6.2%/yr | −6.2%/yr | 3.6 | 0% | 360 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 93 | 5,993−6.1%/yr | −6.1%/yr | 4.30.9× | 36% | 5,880 in 2030−0.3%/yr |
| Hysterectomy, hysteroscopy & ablation | 30 | 3,307−3.1%/yr | −3.1%/yr | 2.60.8× | 12% | 3,820 in 2030+2.4%/yr |
| Incontinence, prolapse & sacral neuromodulation | 39 | 2,574−0.2%/yr | −0.2%/yr | 1.90.8× | 8% | 3,390 in 2030+4.7%/yr |
| Prostatectomy & nephrectomy | 22 | 1,462−0.6%/yr | −0.6%/yr | 1.10.8× | 0% | 1,710 in 2030+2.7%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Ohio
Boston Scientific leads with 53% of company spending on these surgeons in 2025, +17 pts on 2024.
In 2025, 5 companies reported engagement with Illinois’s surgeons worth $27K in consulting, speaking, meals and travel tied to these products, about $185 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.